Page 20 - Program Updates News Today

Investegate announcements from Silence Therapeutics, Silence Provides Pipeline Updates at 2021 R&D Day

On May 27, Governor Sisolak approved Assembly Bill 348, which moves the Patient Protection Commission (PPC) to the Department of Health and Human Services and designates the PPC in law...

On May 27, Governor Sisolak approved Assembly Bill 348, which moves the Patient Protection Commission (PPC) to the Department of Health and Human Services and designates the PPC in law...

New York State Department of Environmental Conservation NYSDEC will hold two public hearings 2:00 PM and 6:00 PM EDT regarding the Department’s proposed regulations revising the State’s Chemical Bulk Storage CBS and Petroleum Bulk Storage PBS Programs.

/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and...

July 8, 5 p.m., Parks & Recreation Committee July 13, 7 p.m. Planning Commission July 14, 3 p.m. Cemetery Commission Aug. 2, 7 p.m. City Council Cass County Board of Commissioners Meets 9 a.m. Tuesday, July 6 Commissioners Board Room 1. 9 a.m. Call to Order b. Pledge of Allegiance. c. Approval of agenda for discussion. (Any requests to be heard not on the proposed agenda are considered for inclusion at this time.) 2. 9:05 a.m. Josh Stevenson - County Administrator a. Consent Agenda c. Cass C...

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 News provided by Share this article Share this article SAN DIEGO, May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021...

Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the first quarter ended March 31, 2021. "We are excited to advance IDE397, a potential best-in-class MAT2A inhibitor, in the Phase 1 dose escalation for evaluation i...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ProQR Announces First Quarter 2021 Operating and Financial Results ProQR Therapeutics N.V.May 6, 2021 GMT Phase 2/3 pivotal  Illuminate  trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the p...